Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The main protease (3CL M pro ) from SARS-CoV-2, the virus that causes COVID-19, is an essential enzyme for viral replication with no human counterpart, making it an attractive drug target. Although drugs have been developed to inhibit the proteases from HIV, hepatitis C and other viruses, no such therapeutic is available to inhibit the main protease of SARS-CoV-2. To directly observe the protonation states in SARS-CoV-2 M pro and to elucidate their importance in inhibitor binding, we determined the structure of the enzyme in complex with the α-ketoamide inhibitor telaprevir using neutron protein crystallography at near-physiological temperature. We compared protonation states in the inhibitor complex with those determined for a ligand-free neutron structure of M pro . This comparison revealed that three active-site histidine residues (His41, His163 and His164) adapt to ligand binding, altering their protonation states to accommodate binding of telaprevir. We suggest that binding of other α-ketoamide inhibitors can lead to the same protonation state changes of the active site histidine residues. Thus, by studying the role of active site protonation changes induced by inhibitors we provide crucial insights to help guide rational drug design, allowing precise tailoring of inhibitors to manipulate the electrostatic environment of SARS-CoV-2 M pro .
Article activity feed
-
SciScore for 10.1101/2021.01.12.426388: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Diffraction data were then reduced and scaled using the Aimless73 program from the CCP4 suite74; molecular replacement using PDB code 6XQS57 was then performed with Molrep from the CCP4 program suite. CCP4suggested: (CCP4, RRID:SCR_007255)Joint X-ray/neutron refinement: The joint X-ray/neutron refinement of ligand-free 3CL Mpro was performed using nCNS76, and the structure was manipulated in Coot. Cootsuggested: (Coot, RRID:SCR_014222)Results from OddPub: Thank you for sharing …
SciScore for 10.1101/2021.01.12.426388: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Diffraction data were then reduced and scaled using the Aimless73 program from the CCP4 suite74; molecular replacement using PDB code 6XQS57 was then performed with Molrep from the CCP4 program suite. CCP4suggested: (CCP4, RRID:SCR_007255)Joint X-ray/neutron refinement: The joint X-ray/neutron refinement of ligand-free 3CL Mpro was performed using nCNS76, and the structure was manipulated in Coot. Cootsuggested: (Coot, RRID:SCR_014222)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-